However, the same clinical trial revealed that only 6.2% of patients maintained any benefit at 6 months post-treatment compared to 0% in the placebo group
for instance, gain-of-function variants in KCNQ2 or KCNQ3 genes, which encode Kv7.2 and Kv7.3 subunits, have been associated with reduced pain sensitivity in individuals carrying a pro-excitatory Nav1.7 mutation, demonstrating how enhanced M-current can confer resilience to neuronal hyperexcitability (Estacion et al., 2023)
Some facial protocols use very superficial intradermal technique - that must be clinician-administered
Vestibular dysfunction in acute traumatic brain injury
Abbreviations: V: vehicle, CS: CagriSema, WM: Weight matched
Petek, Peptides 1998, Proceed